Bibliometric analysis of olaparib and pancreatic cancer from 2009 to 2022: A global perspective.

BACKGROUND

Genetic screening for breast cancer gene 1 ()/ mutations can inform breast/ovarian/pancreatic cancer patients of suitable therapeutic interventions. Four to seven percent of pancreatic cancer patients have germline mutations. genes aid in DNA repair, especially homologous recombination, which impacts genomic stability and cancer cell growth. regulates the cell cycle, ubiquitination, and chromatin remodeling, whereas stimulates the immune response. They predict the efficacy of platinum chemotherapy or polymerase (PARP) inhibitors such as olaparib.

AIM

To determine the trends and future directions in the use of olaparib for pancreatic cancer treatment.

METHODS

To evaluate the trends in how olaparib works in pancreatic cancer, we performed a bibliometric analysis. One hundred and ninety-six related publications were accessed from the Web of Science Core Collection and were published between 2009 and 2022. The analytic parameters included publications, related citations, productive countries and institutes, influential authors, and keyword development.

RESULTS

This study visualizes and discusses the current research, including the present global trends and future directions in olaparib and pancreatic cancer. Overall, this study sheds light on optimizing the use of olaparib in pancreatic cancer treatment, offering valuable guidance for researchers in this field.

CONCLUSION

Our findings identified trends in olaparib and pancreatic cancer, with China and the USA leading and with global cooperation tightening. O'Reilly EM's team and Memorial Sloan-Kettering had the highest output. The was the most cited journal. More PARP inhibitors are emerging, and combination therapy is suggested for future therapeutic trends.